CL2020002876A1 - Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420) - Google Patents

Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)

Info

Publication number
CL2020002876A1
CL2020002876A1 CL2020002876A CL2020002876A CL2020002876A1 CL 2020002876 A1 CL2020002876 A1 CL 2020002876A1 CL 2020002876 A CL2020002876 A CL 2020002876A CL 2020002876 A CL2020002876 A CL 2020002876A CL 2020002876 A1 CL2020002876 A1 CL 2020002876A1
Authority
CL
Chile
Prior art keywords
divisional application
infectious bronchitis
bronchitis vaccine
vaccine
component
Prior art date
Application number
CL2020002876A
Other languages
English (en)
Inventor
Freitas Carla Maria Batista De
Santos Maria Carolina Ferreira Dos
Paul Joseph Dominowski
Harmen Jacob Geerligs
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2020002876A1 publication Critical patent/CL2020002876A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Una vacuna que comprende un componente de antígeno y un componente adyuvante, en donde el componente adyuvante comprende un oligonucleótido inmunoestimulante y una emulsión de agua-en-aceite (W/O), donde el componente antigénico comprende un virus IBD inactivado, y donde el oligonucleótido inmunoestimulante comprende la SEQ ID NO: 8 en una cantidad de 2,5 a 20 µg por dosis.
CL2020002876A 2016-06-02 2020-11-06 Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420) CL2020002876A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344598P 2016-06-02 2016-06-02
US201662365419P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
CL2020002876A1 true CL2020002876A1 (es) 2021-05-07

Family

ID=59215993

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018003420A CL2018003420A1 (es) 2016-06-02 2018-11-30 Vacuna contra la bronquitis infecciosa.
CL2020002876A CL2020002876A1 (es) 2016-06-02 2020-11-06 Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018003420A CL2018003420A1 (es) 2016-06-02 2018-11-30 Vacuna contra la bronquitis infecciosa.

Country Status (15)

Country Link
US (3) US11103573B2 (es)
EP (1) EP3463446A1 (es)
JP (3) JP7659367B2 (es)
KR (6) KR20210068602A (es)
CN (1) CN109152829A (es)
AU (1) AU2017274332B2 (es)
BR (1) BR112018075033A2 (es)
CA (2) CA3025524C (es)
CL (2) CL2018003420A1 (es)
CO (1) CO2018012905A2 (es)
MX (3) MX2018014857A (es)
PH (1) PH12018502525A1 (es)
UA (1) UA126562C2 (es)
WO (1) WO2017210244A1 (es)
ZA (3) ZA201807477B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303252A (zh) * 2020-02-17 2020-06-19 青岛易邦生物工程有限公司 一种规模化生产胚毒类抗原的净化方法
WO2024077025A1 (en) * 2022-10-04 2024-04-11 Zoetis Services Llc Poultry vaccines and methods of protecting poultry

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
CA2238659C (en) * 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1357151A1 (en) 2002-04-26 2003-10-29 ATOFINA Research Improved processing of bimodal polymers
WO2005063284A1 (en) * 2003-12-23 2005-07-14 Intervet International B.V Combination vaccine for poultry
KR101172921B1 (ko) 2004-03-12 2012-08-13 와이어쓰 엘엘씨 감염성 점액낭병 바이러스 항원 분리체 및 백신
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
KR101251707B1 (ko) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
US8679504B2 (en) * 2008-05-22 2014-03-25 University Of Georgia Research Foundation Inc. Poultry viral materials and methods related thereto
CN102076358B (zh) 2008-06-27 2016-08-17 硕腾有限责任公司 新颖的佐剂组合物
AR072976A1 (es) 2008-08-08 2010-10-06 Wyeth Corp Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo
CN101721698B (zh) 2008-10-24 2014-04-02 法罗斯疫苗公司 抗口蹄疫疫苗组合物及其制备和应用
MY160201A (en) * 2008-12-09 2017-02-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
CN102038949A (zh) * 2010-12-29 2011-05-04 青岛易邦生物工程有限公司 鸡新城疫、传染性支气管炎、减蛋综合征、禽流感（h9亚型）四联灭活疫苗的生产方法
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
KR101974382B1 (ko) 2011-04-18 2019-05-03 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 백신 전달 방법
MX382968B (es) 2012-11-16 2025-03-12 United Biomedical Inc Vacuna de emergencia basada en péptidos sintéticos contra la fiebre aftosa.
DK3542819T3 (da) * 2013-05-14 2021-09-20 Zoetis Services Llc Hidtil ukendte vaccinesammensætninger omfattende immunstimulerende oligonukleotider
RU2730011C2 (ru) 2013-09-19 2020-08-14 Зоэтис Сервисиз Ллс Адъюванты на масляной основе

Also Published As

Publication number Publication date
KR20180129926A (ko) 2018-12-05
CO2018012905A2 (es) 2018-12-14
AU2017274332B2 (en) 2024-06-27
JP2023002541A (ja) 2023-01-10
CA3025524A1 (en) 2017-12-07
EP3463446A1 (en) 2019-04-10
BR112018075033A2 (pt) 2019-03-26
KR20210068601A (ko) 2021-06-09
KR20220064417A (ko) 2022-05-18
ZA201807477B (en) 2023-06-28
CL2018003420A1 (es) 2019-01-18
MX2018014857A (es) 2019-03-07
US20190240315A1 (en) 2019-08-08
JP2025041829A (ja) 2025-03-26
US12171825B2 (en) 2024-12-24
AU2017274332A1 (en) 2018-11-22
JP7679340B2 (ja) 2025-05-19
NZ788649A (en) 2025-05-30
JP7659367B2 (ja) 2025-04-09
WO2017210244A1 (en) 2017-12-07
JP2019517526A (ja) 2019-06-24
US20250295752A1 (en) 2025-09-25
ZA202204979B (en) 2022-09-28
KR20220100725A (ko) 2022-07-15
RU2018142329A3 (es) 2020-09-01
MX2022007212A (es) 2022-07-12
RU2018142329A (ru) 2020-06-01
KR20240141211A (ko) 2024-09-25
MX2022012910A (es) 2022-11-14
RU2021117820A (ru) 2021-07-07
NZ748375A (en) 2024-07-26
NZ788650A (en) 2025-08-29
ZA202204980B (en) 2022-09-28
KR20210068602A (ko) 2021-06-09
KR102893877B1 (ko) 2025-12-03
UA126562C2 (uk) 2022-11-02
CN109152829A (zh) 2019-01-04
CA3025524C (en) 2023-03-07
PH12018502525A1 (en) 2019-10-21
CA3175832A1 (en) 2017-12-07
US20220175911A1 (en) 2022-06-09
US11103573B2 (en) 2021-08-31

Similar Documents

Publication Publication Date Title
Baz et al. H5N1 vaccines in humans
PH12019501766A1 (en) Porcine coronavirus vaccines
AR127585A1 (es) Vacuna de arn de virus sincicial respiratorio
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
TW201612316A (en) Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method and application of vaccine composition
CO2019011548A2 (es) Vacunas contra el gallid herpesvirus 3 recombinante que codifican antígenos patogénicos aviares heterólogos
MX376715B (es) Vacuna contra el virus de la diarrea epidemica porcina.
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
JOP20190088A1 (ar) نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
MX388128B (es) Vacuna combinada para cerdos.
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
EA201001478A1 (ru) Вакцина
WO2020012428A8 (en) New vaccines against avian reoviruses
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
AR056733A1 (es) Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos
AR097029A1 (es) Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
PH12022550939A1 (en) Chikungunya virus-like particle vaccine and methods of using the same
MX2020003753A (es) Composicion nasal de vacuna contra hepatitis b y metodo para producir la misma.
MX2012002630A (es) Regimen de inmunizacion por sensibilizacion-refuerzo heterologa contra el virus de la lengua azul.
PH12020550948A1 (en) Vaccines against hendra and nipah virus infection